vTv Therapeutics Inc. - (VTVT) News
Filter VTVT News Items
VTVT News Results
|Loading, please wait...|
VTVT News Highlights
- For VTVT, its 30 day story count is now at 7.
- Over the past 19 days, the trend for VTVT's stories per day has been choppy and unclear. It has oscillated between 1 and 3.
- RWLK, CAPR and LICY are the most mentioned tickers in articles about VTVT.
Latest VTVT News From Around the Web
Below are the latest news stories about vTv Therapeutics Inc that investors may wish to consider to help them evaluate VTVT as an investment opportunity.
vTv Therapeutics Announces Positive Results from Mechanistic Study Indicating No Increased Risk of Ketoacidosis with TTP399 during Acute Insulin Withdrawal in Patients with Type 1 Diabetes
Study achieved primary endpoint of non-inferiority on measurement of key blood ketone levels Patients taking TTP399 reported no events of hypoglycemia, while four events of hypoglycemia were reported in the placebo arm Start-up activities for Phase 3 program ongoing with trials expected to begin in early 2022 HIGH POINT, N.C., Oct. 12, 2021 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq: VTVT) a clinical-stage biopharmaceutical company focused on the development of orally administered treatme
Thinking about buying stock in Camber Energy, Rewalk Robotics, vTv Therapeutics, Quantumscape, or Northern Dynasty Minerals?
NEW YORK , Sept. 27, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for CEI, RWLK, VTVT, QS, and NAK. Full story available on Benzinga.com
Thinking about buying stock in Capricor Therapeutics, vTv Therapeutics, Li-Cycle Holdings, Predictive Oncology, or Rewalk Robotics?
NEW YORK , Sept. 24, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for CAPR, VTVT, LICY, POAI, and RWLK. Full story available on Benzinga.com
vTv Therapeutics Announces Results of Multiple Ascending Dose Study and Development Plan for HPP737, an Oral PDE4 Inhibitor for the Treatment of Psoriasis
HPP737 exhibited favorable safety and tolerability profile, with no dose limiting gastrointestinal side effects
Multiple insiders bought vTv Therapeutics Inc. (NASDAQ:VTVT) stock earlier this year, a positive sign for shareholders
Generally, when a single insider buys stock, it is usually not a big deal. However, when several insiders are buying...
News of regulatory approval or progress would really help to move the needle for these seven biotech penny stocks.
Oral Insulin Market Competitive Research And Precise Outlook 2021 To 2025 -Novo Nordisk A/S, Oramed Pharmaceuticals Inc., vTv Therapeutics
The Global Oral Insulin Market Report 2021 provides an in-depth analysis of key players'' strategies, market growth, product demand, growth factors, technological innovations, regional outlook and global dynamics which includes drivers, challenges, and opportunities dominant in the industry. This Market
vTv Therapeutics (VTVT) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.
HIGH POINT, N.C., Aug. 04, 2021 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq:VTVT) today reported financial results for the second quarter ended June 30, 2021, and provided an update on the progress of its clinical programs.
vTv Therapeutics (VTVT) delivered earnings and revenue surprises of 85.71% and -99.10%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?